Component

Blood glucose in streptozotocin-treated diabetic mice

Glycaemia measured on oral glucose tolerance testing.

1 recorded relationships. Experimental role, claim status and evidence remain attached to each record.

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

What acts on it

  1. Three weeks of oral lariciresinol at 10 mg/kg decreased blood glucose and increased insulin on an oral glucose tolerance test in streptozotocin-treated diabetic mice.

    Experimental context and source evidence
    duration
    3 weeks
    evidence_access
    Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
    experimental_model
    Streptozotocin-treated diabetic mice
    exposure
    Lariciresinol 10 mg/kg orally for 3 weeks
    limitations
    Streptozotocin-induced diabetes models beta-cell destruction rather than the common human disease, and the enantiomer administered is not stated.
    organism
    Streptozotocin-treated diabetic mice
    plain_language
    Three weeks of oral lariciresinol at 10 mg/kg decreased blood glucose and increased insulin on an oral glucose tolerance test in streptozotocin-treated diabetic mice.
    primary_references
    Lariciresinol Displays Anti-Diabetic Activity through Inhibition of α-Glucosidase and Activation and Enhancement of Insulin Signaling. (2022). https://pubmed.ncbi.nlm.nih.gov/35490401/ DOI: 10.1002/mnfr.202100910
    route
    Oral
    tissue
    Blood glucose, insulin and pancreatic histology

    Lariciresinol: five molecules under one name, and the mechanisms each one carries (2026-09-22) · lines 187–196

    Original AI-assisted curation of twelve primary studies, every abstract read and all DOIs cross-checked against live PubMed metadata. Mechanism edges only, with no conclusion or claim of benefit recorded. Three author clusters account for eight of the twelve and carry shared laboratory keys. Study-specific concentrations, negative findings and limitations retained. Not publisher full text. · supports · · source_derived_draft · unverified_draft

    ## lariciresinol-lowers-blood-glucose-in-diabetic-mice Three weeks of oral lariciresinol at 10 mg/kg decreased blood glucose and increased insulin on an oral glucose tolerance test in streptozotocin-treated diabetic mice. Model/species: Streptozotocin-treated diabetic mice Tissue/system: Blood glucose, insulin and pancreatic histology Exposure: Lariciresinol 10 mg/kg orally for 3 weeks Route: Oral Duration: 3 weeks Limits: Streptozotocin-induced diabetes models beta-cell destruction rather than the common human disease, and the enantiomer administered is not stated. Primary reference: Lariciresinol Displays Anti-Diabetic Activity through Inhibition of α-Glucosidase and Activation and Enhancement of Insulin Signaling. (2022). https://pubmed.ncbi.nlm.nih.gov/35490401/ DOI: 10.1002/mnfr.202100910 Access: Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
    Complete structured claim and evidence

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

    This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.

    Evidence, AI assistance and curation standards